Search for: "Boehringer Ingelheim Pharmaceuticals"
Results 141 - 160
of 252
Sorted by Relevance
|
Sort by Date
12 Jun 2013, 12:50 pm
The concerns relate to a number of widely prescribed GLP-1–based therapies, the 2 injectable GLP-1 agonists, exenatide (Byetta, Amylin/Lilly) and liraglutide (Victoza, Novo Nordisk), and the oral DPP-4 inhibitors sitagliptin, saxagliptin (Ongylza, AstraZeneca/Bristol-Myers Squibb), and linagliptin (Tradjenta, Boehringer Ingelheim/Lilly). [read post]
19 Jul 2011, 6:03 am
Here's the list for 2011 so far: Potential Signals of Serious Risks/New Safety Information Identified by AERS, January to March 2011 Product Potential Signal of a Serious Risk/New Safety Information Additional Information (as of May 31, 2011) … [read post]
8 Mar 2012, 7:25 am
While the FDA studies these adverse events, trial lawyers across the nation are standing up for consumer rights, asking manufacturer Boehringer Ingelheim for answers. [read post]
5 Oct 2015, 3:15 pm
Similar Lawsuits Claims For Pradaxa Pradaxa, is another new-generation anticoagulant introduced by Boehringer Ingelheim in October 2010. [read post]
9 Jul 2015, 2:51 pm
AstraZeneca manufactures Farxiga and Xigduo, Jardiance and Glyxambi is made by Lilly and Boehringer Ingelheim. [read post]
9 Jun 2011, 12:43 pm
But Lilly recently struck a deal to promote a rival diabetes drug, Tradjenta, with Germany’s Boehringer Ingelheim using the same sales force. [read post]
7 Jan 2014, 5:19 pm
Tradjenta (linagliptin) is manufactured by Eli Lilly and Boehringer Ingelheim and approved for sale in 2011. [read post]
29 Dec 2009, 9:09 pm
Director Team Leader, International Business Development, Pfizer Bill Bertrand, Senior Vice President, Legal Affairs, General Counsel and Corporate Compliance Officer, MedImmune Adelene Perkins, President and Chief Business Officer, Infinity Pharmaceuticals Michael Leonetti; Head, Health Care Partnerships, Boehringer Ingelheim David Low, Managing Director, Lazard Sanj Singh, CEO, Ade Therapuetics Here is a link to the event where you can get more… [read post]
13 Nov 2023, 4:10 pm
Boehringer Ingelheim Pharmaceuticals, Inc., Williams asks the court to grant review and reverse the 11th Circuit’s ruling. [read post]
27 Oct 2010, 9:30 am
Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals Inc. of Ridgefield, Conn., will be available in 75 milligram and 150 milligram capsules. [read post]
20 May 2009, 4:26 am
When FDA urged stronger warnings, Boehringer Ingelheim Pharmaceuticals (makes Flomax) sent letters to doctors warning them about the potential problems. [read post]
4 May 2011, 10:00 am
Tradjenta is marketed by Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Conn., and Indianapolis-based Eli Lilly Co. [read post]
3 Dec 2009, 10:16 pm
Supporters can click the Make it Happen link and send an email to the CEOs of Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer Inc. and Sequoia Pharmaceuticals Inc. [read post]
26 Oct 2011, 10:06 am
Enter Dabigatran, called by the sexier name Pradaxa, manufactured by Boehringer Ingelheim, is a more recent blood thinner to emerge in the marketplace, gaining approval from the FDA in October 2010. [read post]
3 Feb 2010, 2:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://duncanbucknell.com/subscribe/ Highlights this week included: Temodar (Temozolomide) – US: District Court Delaware: Temador patent unenforceable due to prosecution laches and inequitable conduct: Cancer Research Tech v Barr Labs (Docket Report) (Patent Baristas) (IP Factor) Mirapex (Pramipexole) – US: CAFC: The metes and bounds of obviousness-type double patenting:… [read post]
10 Mar 2010, 5:22 am
(FDA Law Blog) US: Review and correction of patent term adjustment calculation made by the USPTO: Boehringer Ingelheim Pharma GmbH & Co. [read post]
28 Aug 2018, 12:16 am
Case law states that a brand owner can oppose a repackaging of a pharmaceutical product if the repackaging threatens the guarantee of origin, unless certain conditions are met (as laid out in the cases Bristol-Myers Squibb (see C-427/93, C-429/93 and C-436/93) and Boehringer Ingelheim (see C348/04)). [read post]
10 Mar 2010, 5:22 am
(FDA Law Blog) US: Review and correction of patent term adjustment calculation made by the USPTO: Boehringer Ingelheim Pharma GmbH & Co. [read post]
19 Oct 2012, 7:32 am
Common Complaints and Grounds of Pradaxa Lawsuits Product Liability: Majority of Pradaxa lawsuits sue the Boehringer Ingelheim for its inability to warn about the drug side effects. [read post]
7 Jan 2015, 10:59 am
Although it’s a small company, that figure puts it in the company of major drug makers like Boehringer Ingelheim and Novo Nordisk, which market a lot of different products. [read post]
